摘要
采用随机、双盲、安慰剂对照法用硝苯啶对42例收缩功能正常或大致正常,舒张功能障碍性心衰患者治疗,并测定治疗前后血小板胞浆游离Ca^(2+)、红细胞内Ca^(2+)及其膜Ca^(2+)-Mg^2+ATPase活性与心功能指标。结果表明,安慰组各项指标无显著变化;治疗组心功能指标明显改善并伴Ca^(2+)系统指标相应变化。其中Ⅱ度心衰恢复至Ⅰ度,Ⅰ度心衰指标明显改善,但未能至正常水平。提示:①心脏病早期可能已发生Ca^(2+)运转与心功能异常;②Ca^(2+)运转异常可能是舒张功能障碍的原因之一,Ca^(2+)拮抗剂可能是通过纠正Ca^(2+)运转异常而改善舒张功能。
Platelet cytoplasma free Ca2+, intraerythrocyte Ca2+, activity of Ca2+-Mg2+-ATPase on erythrocyte membrane and cardiac function of 42 patients with heart failure (HF), resulted from abnormal diastolic function, have been measureed before and after nifedipine administration under random sampling, double-blind and placebo conditions. The results showed that all the parameters showed no remarkable changes in patients of the placebo group. Cardiac function of treatment group improved significantly while there was corresponding changes in Ca2+ transport. During treatment, 8Ⅱ° HF was switched over to Ⅰ° HF, and Ⅰ° HF improved significantly, yet failed to reach normal level. These suggested that(1) abnormality of both Ca2+ transport and cardiac function can take place in early stage of heart diseases; (2) abnormal Ca2+ transport may be one of the important factors producing heart failure with abnormal diastolic function. Therapeutic effect of Ca2+ channel blocker may be related to effect on Ca2+ transport.
出处
《解放军医学杂志》
CAS
CSCD
北大核心
1991年第6期423-426,共4页
Medical Journal of Chinese People's Liberation Army
关键词
硝苯啶
心力衰竭
钙离子
Nifedipine Diastolic dysfunction Heart failure Ca2+ transport
